Cello Group plc (LON:CLL)‘s stock had its “buy” rating restated by N+1 Singer in a research report issued to clients and investors on Tuesday. They presently have a GBX 131 ($1.69) target price on the stock. N+1 Singer’s target price would indicate a potential upside of 4.38% from the stock’s current price.

CLL has been the topic of several other research reports. FinnCap reaffirmed a “buy” rating and issued a GBX 132 ($1.71) price objective on shares of Cello Group plc in a research note on Thursday, January 19th. Peel Hunt reaffirmed a “buy” rating and issued a GBX 130 ($1.68) price objective on shares of Cello Group plc in a research note on Wednesday, January 11th.

Shares of Cello Group plc (LON:CLL) traded up 2.39% during midday trading on Tuesday, reaching GBX 128.50. The company had a trading volume of 317,705 shares. The firm’s market capitalization is GBX 111.98 million. Cello Group plc has a 12-month low of GBX 91.67 and a 12-month high of GBX 130.00. The company has a 50 day moving average of GBX 122.76 and a 200 day moving average of GBX 109.33.

The business also recently disclosed a dividend, which will be paid on Friday, May 26th. Stockholders of record on Thursday, May 4th will be paid a GBX 2.40 ($0.03) dividend. The ex-dividend date is Thursday, May 4th. This represents a dividend yield of 1.98%. This is an increase from Cello Group plc’s previous dividend of $1.00.

TRADEMARK VIOLATION WARNING: This article was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://www.americanbankingnews.com/2017/05/09/n1-singer-reiterates-buy-rating-for-cello-group-plc-cll.html.

Cello Group plc Company Profile

Cello Group plc is a United Kingdom-based healthcare and consumer strategic marketing company. The Company is engaged in providing market research, consulting and direct marketing services. The Company operates through two segments: Cello Health and Cello Signal. The Cello Health Division provides market research, consulting and communications services principally to the Company’s pharmaceutical and healthcare clients.

Receive News & Ratings for Cello Group plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cello Group plc and related companies with MarketBeat.com's FREE daily email newsletter.